

ANNUAL GENERAL MEETING OF PROLIGHT DIAGNOSTICS AB (PUBL) ON 30 JUNE 2025

The annual general meeting (AGM) of Prolight Diagnostics AB (publ) took place on 30 June 2025 in Lund. Full information regarding the decisions of the AGM is available on the company's website, www.prolightdx.com. The AGM resolved in accordance with all of the motions presented in the notification of the AGM.

Resolution regarding the adoption of the income statement and the balance sheet, as well as discharge from liability

The AGM resolved to adopt the income statement and the balance sheet for the parent company and the group for the previous financial year. The board of directors and the managing director were discharged from liability for the same period.

Resolution on the appropriation of the company's result in accordance with the adopted balance sheet

The AGM resolved that no dividend be paid for the previous financial year, and that the result will be carried forward.

Board of directors

The AGM resolved that the board of directors shall consist of seven board members with no deputies. Maria Holmlund, Ulf Bladin, Steve Ross, Aileen McGettrick, Tobias Volker and Kiarash Farr were re-elected as board members, and Fredrik Alpsten was elected as a new board member. Fredrik Alpsten was elected as chairman of the board.

Resolution pertaining to directors' fees

The AGM resolved that a fee of SEK 400,000 be allocated to the chairman of the board and that a fee of SEK 240,000 be allocated to each of the other board members. The said fees include remuneration for committee work, if applicable. A board member who is employed by the company or any of its subsidiaries shall not receive a fee.

Auditor

The AGM resolved to re-elect the registered accounting firm, Mazars AB, as the company's auditor until the end of the next AGM. The authorised auditor, Jesper Ahlkvist, will serve as the auditor in charge. Fees to the auditor are paid against approved invoices.

Authorisation of the Board of Directors to resolve on issue of shares, warrants and/or convertible instruments

The AGM resolved, in accordance with the board's proposal, to authorise the board to, on one or several occasions during the period until the next AGM and within the limits of the articles of association, issue new shares, warrants, and/or convertibles. The board of directors is authorised to issue new shares, warrants, and/or convertibles with deviation from the shareholders' pre-emption rights and/or provisions for contribution in kind, set-off or other conditions.

Authorisation of the Board of Directors to resolve on issue of shares

The AGM resolved, in accordance with the board's proposal, to authorise the board to, on one or several occasions during the period until the next AGM and within the limits of the articles of association, issue new shares. The board of directors is authorised to issue new shares, warrants, and/or convertibles with deviation from the shareholders' pre-emption rights and/or provisions for contribution in kind, set-off or other conditions to enable issuing additional shares to investors in the event of oversubscription in the rights issue resolved by the board on 21 May 2025 or issue shares to those who have entered into guarantee commitments with the Company in connection with the rights issue resolved by the board on 21 May 2025.

For further information, please contact:

Ulf Bladin, CEO

E-mail: info@prolightdx.com

Phone: +46 73 582 39 87

Company website: www.prolightdx.com

About Us

Prolight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments

Annual general meeting of Prolight Diagnostics AB (publ) on 30 June 2025